SATHGEN

THERAPEUTICS

State-of-the-art science for the hardest-to-treat cancers

We are seeking strategic partners for out-licensing, co-development and investment for our exciting lead molecule that has shown robust safety and efficacy against one of the most vicious of cancers - TNBC (triple negative breast cancer).

Drug Development and Commercialization

Significant Patents

Patent for MSP008-22 anti-cancer compound granted in USA and Japan.

Patent for Synthesis of Cleistanthin A and its derivatives thereof granted in India, USA, Germany, Netherlands, France, UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.

Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa